Search | Webyourself Social Media Platform

Dhanashri Patil added article Health
2024-05-24 11:48:38 -

Cosentyx Drug (secukinumab): A Novel Biologic Therapy for Moderate to Severe Plaque Psoriasis
Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds to and inhibits interleukin-17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in inflammatory and immune responses. Cosentyx was developed by Novartis Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of moderate to severe plaque psoriasis in...

0 Comments 0 Shares 680 Views 0 Reviews

Please log in to like, share and comment!
Ishika Cmi added article Health
2024-04-04 09:04:22 -

Cosentyx Market Dynamics: A Comprehensive Analysis of Influencing Factors
The Cosentyx Drug Market has witnessed exponential growth in recent years, driven by a confluence of factors shaping its trajectory. A significant market driver is the escalating prevalence of autoimmune diseases globally. Conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis have become increasingly common, necessitating effective treatment options like Cosentyx. This...

0 Comments 0 Shares 942 Views 0 Reviews

Please log in to like, share and comment!
Ishika Cmi added article Health
2024-03-13 06:53:43 -

Navigating Market Dynamics: A Comprehensive Overview of the Cosentyx Drug Market
The global Cosentyx Drug Market is estimated to be valued at USD 5.32 Bn in 2024 and is expected to exhibit a CAGR of 7.4% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Conducting a PEST analysis offers a comprehensive understanding of the external factors influencing the Cosentyx Drug Market. Politically, regulatory...

0 Comments 0 Shares 1046 Views 0 Reviews

Please log in to like, share and comment!
Avantika Gorule added article Health
2024-08-20 11:44:45 -

The Cosentyx Drug Market is driven by growing prevalence of psoriasis and psoriatic arthritis
The Cosentyx drug market is mainly driven by the growing prevalence of psoriasis and psoriatic arthritis globally. Cosentyx is a human monoclonal antibody used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by selectively binding to interleukin-17A (IL-17A), preventing it from inducing inflammation. Cosentyx provides long-lasting relief...

0 Comments 0 Shares 402 Views 0 Reviews

Please log in to like, share and comment!